When do you consider re-treatment with lenalidomide in later line therapy for relapsed multiple myeloma?
Are there scenarios where you would use a higher dose of lenalidomide in a novel doublet or triplet (eg. relapse on lenalidomide maintenance)?
Answer from: Medical Oncologist at Academic Institution
It is a challenging question due to the fact all studies post lenalidomide failure even in maintenance never included lenalidomide based therapy in first up to third line of therapy: such as Dara/Pom/dex, Dara/Car/dec, Elo/Pom/dex, Pom/Vel/dex … some argue that since the patient was on low do...
Sign in or Register to read more